BioTuesdays

Tag - APRE

HCW starts Aprea Therapeutics at neutral; PT $30

H.C. Wainwright initiated coverage of Aprea Therapeutics (NASDAQ:APRE) with a “neutral” rating and $30 price target. The stock closed at $37.90 on June 19. “We see more downside risk heading into pivotal data,” writes...